Blogs and Insights on Neuroscience Research
MyClad Study in PhoenixA Clinical Trial Evaluating Oral Cladribine in Generalized Myasthenia Gravis
Arizona Neuroscience Research is now enrolling participants in the MyClad clinical trial, a Phase 3 study evaluating a new formulation of oral cladribine in adults with generalized myasthenia gravis. The MyClad study is designed to assess the efficacy and safety of oral cladribine compared with placebo in participants with generalized myasthenia gravis, also known as…
Phoenix Migraine Relief: Join the MINT-E Episodic Migraine Clinical Trial at Arizona Neuroscience Research
If you’re searching for migraine treatment Phoenix AZ or a trusted research site in Arizona where you can access innovative therapies, you’ve found the right place. At Arizona Neuroscience Research (ANR) in Phoenix, we are committed to advancing the science of headache care through clinical trials that offer patients opportunities beyond standard treatment. One of…
Phoenix Migraine Relief: Join the MINT-E Episodic Migraine Study at ANR
Arizona Neuroscience Research (ANR) in Phoenix is now enrolling adults with episodic migraine in the MINT-E clinical trial (NCT07018700), testing XEOMIN® (incobotulinumtoxinA) for migraine prevention. If you experience 0-14 migraine days per month, this trial offers no-cost treatment, expert headache specialist oversight, and neurology research close to home. Ideal for residents of Phoenix, Scottsdale, Tempe,…
Chronic Migraine Relief in Phoenix: How You Can Join the MINT-C Trial at ANR
Arizona Neuroscience Research (ANR) in Phoenix is now enrolling adults with chronic migraine in the Phase 3 MINT-C clinical trial (NCT07018713) using XEOMIN® (incobotulinumtoxinA) for prevention. This opportunity is ideal for people living in Phoenix, Scottsdale, Tempe, Mesa, Chandler, Paradise Valley, Arcadia, and Biltmore who’ve had 15+ headache days per month and need better migraine…
Phoenix Epilepsy Breakthrough: Join the POWER-1 Focal Epilepsy Study at ANR
Meta SummaryArizona Neuroscience Research (ANR) in Phoenix is enrolling adults with focal epilepsy in the POWER-1 study (PRAX-628-321). PRAX-628 is an investigational therapy designed to reduce seizures for patients who continue to have breakthrough episodes despite current medications. Valley residents in Scottsdale, Tempe, Mesa, Chandler, Arcadia, Biltmore, and Paradise Valley may receive no-cost treatment, expert…
Phoenix Epilepsy Breakthrough: Join the POWER-1 Focal Epilepsy Study at ANR
Arizona Neuroscience Research (ANR) in Phoenix is now enrolling adults with focal epilepsy in the POWER-1 study (PRAX-628-321). This global trial is testing an investigational drug, PRAX-628, designed to reduce seizures in patients who continue to experience them despite current medications. Participants may receive no-cost study care, close monitoring, and access to investigational therapy at…
Phoenix Epilepsy Breakthrough: Enroll in the Partial-Onset Epilepsy Study at ANR
Arizona Neuroscience Research (ANR) in Phoenix is now enrolling adults with partial-onset seizures in a global clinical trial (NCT04513860). This study is testing an investigational medication to reduce seizure frequency and improve daily life for people with epilepsy. Participants may receive no-cost study care, medication, and expert monitoring at ANR’s two Phoenix locations. For Valley…
Chronic Migraine Relief in Phoenix: Enroll in the MINT-C Clinical Trial at ANR
Arizona Neuroscience Research (ANR) in Phoenix is now enrolling adults with chronic migraine in the MINT-C clinical trial (NCT07018713), testing XEOMIN® (incobotulinumtoxinA) for prevention. Participants may receive no-cost study care, medication, and close monitoring across ~14 visits in one year. This Phase 3 study offers Valley residents—including those in Scottsdale, Chandler, Tempe, Mesa, Paradise Valley,…
Phoenix Migraine Relief: Join the MINT-E Episodic Migraine Study at ANR
Arizona Neuroscience Research (ANR) in Phoenix is now enrolling adults with chronic migraine in the MINT-C clinical trial (NCT07018713), testing XEOMIN® (incobotulinumtoxinA) for migraine prevention. If you have migraines 15 or more days per month, with at least 8 migraine-type days, and your migraine onset was before age 50, you may qualify. The study includes…
Phoenix Neurology Leaders: Join the MOTRIC-CD Cervical Dystonia Clinical Trial at ANR
Arizona Neuroscience Research (ANR) in Phoenix is enrolling adults with cervical dystonia in the MOTRIC-CD clinical trial (NCT06830642). This international Phase 3 study is evaluating a potential new therapy for people living with cervical dystonia, a painful neurological disorder marked by involuntary neck muscle contractions and abnormal head postures. Participants may receive study-related care and…